Patent · US Active

Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization

US8742102B2 · kind B2 · utility

4Cited by

2References

13Claims

0Family size

Assignee

POXEL · FR

Inventors

Matthias Helmreich · Heidelberg, DE
Claus-Peter Niesert · Seeheim-Jugenheim, DE
Daniel Cravo · Sartrouville, FR
Gerard Coquerel · Boos, FR
Guillaume Levilain · Rouen, FR
Saoussen Wacharine-Antar · العوينة, TN
Pascal Cardinael · Isneauville, FR

Key dates

Filing date	Mar 26, 2010
Grant date	Jun 3, 2014
Priority date	—
Expiry date	Nov 29, 2030

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P3/10
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A new process for the enantiomeric separation of racemic 3,6-dihydro-1,3,5-triazine derivatives for the treatment of disorders associated with insulin-resistance syndrome, by preferential crystallization.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.